fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Arexvy is accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk – GSK

Written by | 14 Feb 2024

GSK plc announced that the FDA has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged… read more.

First RSV vaccine to protect infants and older adults

Written by | 7 Sep 2023

EU medicines regulators have approved a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is the first RSV vaccine indicated for passive immunisation… read more.

EU approves Abrysvo for respiratory syncytial virus – Pfizer

Written by | 3 Sep 2023

Pfizer announced that the European Commission (EC) has granted marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to help protect both… read more.

US CDC recommends Beyfortus for prevention of respiratory syncytial virus – Sanofi /AstraZeneca

Written by | 14 Aug 2023

The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously 10 to 0 to recommend routine use of Sanofi and AstraZeneca’s… read more.

CHMP recommends Abrysvo the first RSV vaccine to protect infants up to 6 months of age and older adults – Pfizer

Written by | 31 Jul 2023

The CHMP has recommended granting a marketing authorization for Pfizer’s Abrysvo (bivalent, recombinant), a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is… read more.

MHRA (UK) approves Arexvy for prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older – GSK

Written by | 19 Jul 2023

GSK plc announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for active immunisation for the prevention of lower… read more.

EU approves Arexvy for respiratory syncytial virus – GSK

Written by | 11 Jun 2023

GSK announced that the European Commission has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by… read more.

Experts call for monitoring of respiratory vaccine after trials suggest possible increase in preterm births

Written by | 15 May 2023

Experts have called for further scrutiny of a new Pfizer vaccine given during pregnancy to prevent respiratory infection in infants, after trials of a similar GSK vaccine were stopped… read more.

Got the sniffles? Here’s how to make the right decision around family gatherings

Written by | 23 Nov 2022

With what some are calling a “tripledemic” of COVID-19, the influenza virus and respiratory syncytial virus, or RSV, soaring in many parts of the country, the holiday season… read more.

Respiratory Syncytial Virus (RSV) responsible for more than 100,000 deaths worldwide in children under five in 2019

Written by | 22 May 2022

Peer-reviewed/Literature review and Modelling/People Acute lower respiratory infection caused by Respiratory Syncytial Virus (RSV) contributes substantially to the global mortality burden in children, with RSV estimated to cause one… read more.

Infant deaths from RSV are much higher than previously known

Written by | 4 Feb 2022

Nearly one in ten of all deceased infants under 6 months old were infected with Respiratory Syncytial Virus. A new study found that nearly one in ten of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.